Key facts
- This page summarizes Thomas C. Harding's Form 4 filing for Clovis Oncology, Inc..
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 03 Feb 2022, 15:15.
Thomas C. Harding - 01 Feb 2022 Form 4 Insider Report for Clovis Oncology, Inc.
- Reporting relationship
- Senior Vice President and Chief Scientific Officer
- Issuer ticker
- N/A
- Reported as of
- 01 Feb 2022
- Net transaction value
- -$4,108
- SEC form
- 4
- Accepted by SEC
- 03 Feb 2022, 15:15:59 UTC
- Prior SEC filing
- 04 Jan 2022
- Next SEC filing
- 03 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas Harding
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas C. Harding filed Form 4 for Clovis Oncology, Inc. on 03 Feb 2022.
Change
- Previous filing in this sequence was filed on 04 Jan 2022.
- Current net transaction value: -$4,108.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLVS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,563
- Change %
- +29%
- Price
- Shares after
- 6,958
- Date
- 01 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
CLVS
transaction
Common Stock
Sale
- Transaction value
- $1,829
- Shares
- -943
- Change %
- -14%
- Price
- $1.94*
- Shares after
- 6,015
- Date
- 02 Feb 2022
- Ownership
- Direct
- Footnotes
- F2, F3
CLVS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,813
- Change %
- +30%
- Price
- Shares after
- 7,828
- Date
- 01 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
CLVS
transaction
Common Stock
Sale
- Transaction value
- $2,122
- Shares
- -1,094
- Change %
- -14%
- Price
- $1.94*
- Shares after
- 6,734
- Date
- 02 Feb 2022
- Ownership
- Direct
- Footnotes
- F2, F3
CLVS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +182
- Change %
- +12%
- Price
- Shares after
- 1,733
- Date
- 01 Feb 2022
- Ownership
- By wife
- Footnotes
- F1
CLVS
transaction
Common Stock
Sale
- Transaction value
- $157
- Shares
- -81
- Change %
- -4.7%
- Price
- $1.94*
- Shares after
- 1,652
- Date
- 02 Feb 2022
- Ownership
- By wife
- Footnotes
- F2, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLVS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,563
- Change %
- -20%
- Price
- $0.000000
- Shares after
- 6,250
- Date
- 01 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,563
- Exercise price
- Footnotes
- F1, F5
CLVS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,813
- Change %
- -11%
- Price
- $0.000000
- Shares after
- 14,500
- Date
- 01 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,813
- Exercise price
- Footnotes
- F1, F6
CLVS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -182
- Change %
- -11%
- Price
- $0.000000
- Shares after
- 1,450
- Date
- 01 Feb 2022
- Ownership
- By wife
- Underlying class
- Common Stock
- Underlying amount
- 182
- Exercise price
- Footnotes
- F1, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Footnote F2
Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
Footnote F3
This transaction was executed in multiple trades at prices ranging from $1.89 to $1.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F4
This transaction was executed in multiple trades at prices ranging from $1.89 to $1.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F5
On February 1, 2019, the reporting person was granted 25,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Footnote F6
On January 31, 2020, the reporting person was granted 29,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Footnote F7
On January 31, 2020, the reporting person's wife was granted 2,900 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
SEC remarks
Senior Vice President and Chief Scientific Officer